MeerMinder Bedrijfsinformatie

UCB | Inspired by patients. Accept Close Top of this page Skip navigation, go straight to the content UCB - Inspired by patients. Home Patients Overview Conditions CNS Epilepsy ADHD Memory problems Narcolepsy Parkinson's disease Restless Legs Syndrome (RLS) Immunology Allergies Ankylosing spondylitis Crohn's disease Juvenile rheumatoid arthritis Osteoporosis Psoriatic arthritis Respiratory disorders Rheumatoid arthritis Systemic lupus (SLE) Family Planning and Pregnancy Initiative Testimonials Crohn's disease Barbara Carrie Craig Miranda Ally Epilepsy Alexander Beatriz Bryan Griffin Catherine Giuseppe Heather Overton Jerome Lloyd Wieke Parkinson's disease Alun Carlos Christer Jesus Sheila Veronica Wolfgang Rheumatoid arthritis Alison Alice Peterson Clinical trials About clinical trials FAQ Phase I Phase II Phase III Phase IV UCB policy Trial information search Trial results search Patient Programmes Support of patient organisations in Europe 2013 2012 2011 2010 Canine Assistants programme Links Allergies Crohn's disease Epilepsy Narcolepsy Parkinson's disease Restless legs syndrome Rheumatoid arthritis Parkinson's Well-Being Map™ ES Magazine Healthcare Professionals Overview Education General Information Accredited Medical Education Eligibility Grant Application Requirements Types of Programmes Considered Areas of Interest Axial Spondyloarthritis Crohn’s disease Epilepsy Family Planning and Pregnancy in Immunological Diseases Parkinson’s Disease Psoriatic Arthritis Restless Legs Syndrome Rheumatoid Arthritis Systemic Lupus Erythematosus Process for Application Investigator-Initiated Studies Immunology Summit 2014 Investors Overview UCB in brief UCB today Cimzia® Vimpat® Neupro® Keppra® UCB tomorrow Pipeline romosozumab epratuzumab brivaracetam Financials Key figures Full year overview Half-year overview Annual reports Annual reports 2005-2009 Annual reports 2000-2004 Interim reports Financials 2013 Financials 2012 Financials 2011 Financials 2010 Financials 2009 Financials 2008 Financials 2007 Financial reports - FR Financial reports - NL Bonds EMTN Institutional Eurobond 2009 Institutional Eurobond 2013 Perpetual bond Retail Bond 2009 Retail Bond 2013 Retail bond public exchange offer EMTN Notes Share info Governance Shareholders information Shareholders meeting Shareholders meeting 2013 Shareholders meeting 2012 Shareholders meeting 2011 Shareholders meeting 2010 Shareholders meeting 2009 Shareholders meeting 2008 Corporate governance Principles, codes and guidelines Governance reports Corporate governance statements FR Corporate governance statements NL News Magazine contact Media Overview News Resources Press Contact Job Seekers Overview Our company Our culture and people Your career Leadership and personal development Compensation and company benefits Striking the right work-life balance Traineeships United Kingdom Belgium Applying to UCB Australia Austria Belgium Brazil Bulgaria Canada China and Hong Kong Czech Republic Denmark Finland France Germany Greece India Italy Luxembourg Mexico Netherlands Norway Poland Portugal Romania Russia Slovakia Spain Sweden Switzerland Turkey UK and Ireland US About UCB Overview Vision Strategy History Management Facts and figures Company Key strengths Financials Pipeline Research & Development Partners CSR UCB Societal Responsibility Fund CSR @ UCB CSR reporting CSR governance CSR performance Patients Access to healthcare Quality Drug safety Connecting with patients Gaining first-hand insights from patients Enabling patients to learn from each other Interacting appropriately with patient organisations Encouraging a more informed, open dialogue Patient solutions Other initiatives Ethics Bio-ethics Animal welfare in biopharmaceutical research Strictly regulated environment Ethical committees in place 3Rs - Replacement, Reduction and Refinement Clinical trials Increasing transparency Respecting good clinical practices Sales & marketing Planet CO2 Purchasing Waste Soil Magazine Products Overview Product list CNS Keppra® Neupro® Metadate CD™ Nootropil® Xyrem® Vimpat® Immunology Cimzia® - Ankylosing spondylitis Cimzia® - Axial spondyloarthritis Cimzia® - Crohn's disease Cimzia® - Psoriatic arthritis Cimzia® - Rheumatoid arthritis Xyzal® Zyrtec® Tussionex® Lortab™ R&D Overview Pipeline UCB's development pipeline Info centre Drug development process How drugs are named NCE & NBE drug discovery overview Facts & figures UCB periodic table UCB's definition of severe diseases Partnerships People Scientific Advisers to UCB Data Transparency Clinical Study Information Tech Access Overview Antibody programme Our antibody technology Additional capabilities Applying to the antibody programme FAQ's Magazine B2B Overview Suppliers Australia Austria Belgium Bulgaria Canada China Czech Republic Denmark Finland France Germany Greece Hungary Japan India Ireland Italy Korea Luxembourg Mexico Norway Poland Portugal Romania Russia Slovakia Spain Sweden Switzerland The Netherlands Turkey UK USA Sourcing/Bidding   Latest News 23-Sep-2014 Acquisition of own shares 16-Sep-2014 New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 01-Sep-2014 New indication for VIMPAT® (lacosamide): UCB’s anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset seizures Magazine Supporting people with osteoporosis Supporting people with osteoporosis Posted by Fiona De Hemptinne, Patient Solutions Team 16-Oct-2014 UCB honoured for work on lupus UCB honoured for work on lupus Posted by Lisa Pisenti, Lupus Patient Solutions Team 15-Oct-2014 © 2007 - 2014 UCB S.A., Belgium. All rights reserved Partnering Legal notice & Privacy Policy Cookie Policy Contact Print Site map Last updated on: October, 20, 2013 Search Submit Share RSS-Feed LinkedIn YouTube Twitter